Trianni Inc. and animal health company Zoetis announced July 7 a collaboration for the development of transgenic monoclonal antibody platforms for the discovery of new veterinary treatments.
Trianni is a privately held biotech company specializing in antibody discovery technology. Its transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology.
“We are confident that the application of Trianni’s proven transgenic human monoclonal antibody discovery platform technology to the veterinary field will add value to Zoetis's product development programs," Trianni president and chief executive officer Matthias Wabl said.
"We appreciate Trianni's experience in the development of therapeutic antibody platform capabilities and look forward to working with them on innovations for animal health," said Catherine A. Knupp, Zoetis executive vice president and president of research and development. "This collaboration will enhance our internally developed pipeline of novel monoclonal antibodies and hasten the development of therapeutics that could transform the way veterinarians treat a range of diseases in animals."
No financial details were disclosed.
Trianni is headquartered in San Francisco, Cal.
Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals, with product sales in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion and had approximately 10,600 employees.